Trial NCT05087368
Publication Costa Clemens, Open Forum Infect. Dis., 2022
Primary outcome on the report: Immune response assessed by enzyme-linked immunosorbent assay (ELISA) as immunoglobulin G antibodies against SCB-2019 S-protein on day 15... ELISA antibody titers against SCB-2019 S-protein expressed as geometric mean titers (GMTs), geometric mean-fold rise in titers over baseline (GMFR), and seroconversion rates (SCRs) on days 15 and 29. Seroconversion was defined as a≥4-fold increase in post-vaccination titer in those with a baseline titer above the lower limit of quantitation (LLOQ) or a postvaccination titer ≥4-fold the LLOQ in those with no detectable activity at baseline.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.